Navigation Links
CryoCath Provides Update on Patent Infringement Lawsuit
Date:2/14/2008

http://www.cryocath.com Toronto Stock Exchange Symbol: CYT

MONTREAL, Feb. 14 /PRNewswire-FirstCall/ - CryoCath(R) Technologies Inc., the global leader in cryotherapy products to treat cardiac arrhythmias, today provided an update on the enforcement of its patent portfolio.

Since its inception 13 years ago CryoCath has been, and continues to be the clear leader in innovation in the field of cryotherapy devices with cardiac applications and will continue to vigorously enforce its patent rights. CryoCath owns over 100 issued patents world-wide and has more than 100 patent applications pending. In the last five years, CryoCath has filed over 140 patent applications. Many of CryoCath's pending applications are expected to issue between 2008 and 2010, continuing to strengthen CryoCath's intellectual property position.

In October 2007, CryoCath filed a U.S. patent infringement suit against CryoCor, Inc. alleging infringement of six patents. Since that time, the United States Patent and Trademark Office (USPTO) has issued CryoCath two additional patents, U.S. Patent Nos. 7,303,554 and 7,318,821. CryoCath will amend its complaint to assert these patents in this patent infringement suit.

In early February 2008, CryoCath also filed a claim against CryoCor, alleging infringement of a ninth CryoCath patent, U.S. Patent # 5,147,355 entitled "Cryoablation Catheter and Method for Performing Cryoablation" issued to Friedman. Additionally CryoCath believes CryoCor and co-plaintiff AMS Research Corporation assert AMS's patents in their January 2008 action against CryoCath in a manner that illegally extends at least one patent beyond its scope. Therefore, CryoCath filed counterclaims alleging patent misuse, antitrust, and unfair competition. CryoCath believes CryoCor's case is without merit, and that it does not infringe the two patents asserted in the January 2008 action or the foreign counterparts.

Last month, the USPTO declared an Interference to determine the first to invent certain pre-cooling technology. By declaring the Interference, the USPTO allows CryoCath to get involved and present evidence to demonstrate CryoCath's priority to the technology. The USPTO operates under a system of "first-to-invent" rather than "first-to-file". Therefore, CryoCath now has the opportunity to present evidence that will establish it was indeed first-to-invent the pre-cooling technology at issue in the Interference and claimed in a subset of claims in the two CryoCath patents.

CryoCath's two patents at issue in the Interference, also asserted in the October 2007 action, claim priority to an application filed in January 1999. Consistent with the process of innovation, CryoCath invented this technology before it filed its January 1999 application and well before the August 2000 filing date relied on by CryoCor in requesting the Interference. CryoCath believes the USPTO will resolve the Interference in its favor.

CryoCath believes its strong infringement position for all six of its patents presently asserted, its two new patents that will be asserted in the October 2007 action, and its Friedman patent asserted in February 2008, will effectively protect CryoCath's business interests. CryoCath is also confident that the USPTO will conclude from CryoCath's participation in the Interference that CryoCath was the first to invent the technology at issue.

"Our team at CryoCath has worked long and hard to successfully build a strong intellectual property portfolio, creating the foundation on which our success is built," said Jan Keltjens, President and CEO of CryoCath. "We will defend our company's and stakeholders interests vigorously. Resolution of the ongoing dispute may take several years. We expect them to be resolved completely to our satisfaction and that CryoCath's leading efforts to create and commercialize our unique and innovative technology and to enforce our substantial intellectual property covering that technology will be fully recognized."

About CryoCath

CryoCath - http://www.cryocath.com - is a medical technology company that leads the world in cryotherapy products to treat cardiac arrhythmias. With a priority focus on providing physicians with a complete solution of catheter products to treat cardiac arrhythmias, CryoCath has multiple products approved in the U.S., across Europe and several ROW countries. The Company is developing additional products to expand its pipeline of products to treat cardiac arrhythmias.

This press release includes "forward-looking statements" that are subject to risks and uncertainties, including with respect to the timing of regulatory trials and their outcome. For information identifying legislative or regulatory, economic, climatic, currency, technological, competitive and other important factors that could cause actual results to differ materially from those anticipated in the forward looking statements, see CryoCath's annual report available at http://www.sedar.com under the heading Risks and Uncertainties in the Management's Discussion and Analysis section.


'/>"/>
SOURCE CryoCath Technologies Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CryoCath files patent infringement lawsuit
2. CryoCath to present at CIBC Healthcare Conference
3. CryoCath to present at Piper Jaffray and BMO Healthcare conferences
4. CryoCath announces 2007 fourth quarter and fiscal year end financial results
5. CryoCath intends to contest patent infringement claim by CryoCor, Inc.
6. CryoCath to Hold First Quarter 2008 Conference Call and Webcast
7. Study provides hope that some transplant patients could live free of antirejection drugs
8. Study provides hope that some transplant patients could live free of anti-rejection drugs
9. USAID Provides Additional Wildfire Assistance to Greece
10. LifeMasters Provides Tips for Maintaining a Healthy Blood Cholesterol Level
11. New knock-out gene model provides molecular clues to breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology: